ArticleCNS neuroscience & therapeutics2026
Application of a Combined Transcriptomics and Proteomics Analysis Approach to Explore Potential Mechanisms of Biomarkers in NIHL.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to elucidate the molecular mechanisms underlying noise-induced hearing loss (NIHL) by analyzing cochlear protein expression and transcriptional profiles at multiple time points after noise exposure. This investigation aimed to identify key biomarkers and potential therapeutic targets to mitigate the irreversible effects of NIHL.
methodsCochlear specimens were collected from animal models at 1, 14, and 28 days post-noise exposure. Integrated transcriptomic and proteomic analyses were performed to identify differentially expressed genes and proteins, followed by bioinformatic analyses to explore their functional roles. Reverse transcription quantitative PCR (RT-qPCR) was used to validate the expression levels of selected genes.
resultsSix biomarkers (Gm37065, Cd5l, F930017D23Rik, Eldr, Gm30948, and Tspo2) showed strong correlations with NIHL. RT-qPCR validation revealed a significant decrease in mRNA expression of five of these genes, including Gm37065, across all experimental groups, while the expression of Cd5l remained unchanged. Functional analyses indicated that disruptions in mitochondrial energy metabolism and cochlear inflammation are key contributors to NIHL pathogenesis.
conclusionThis study reveals dynamic molecular changes associated with NIHL progression and identifies novel biomarkers and pathways with potential therapeutic relevance. Further mechanistic validation and functional studies are necessary to elucidate the roles of Tspo, Cd5l, and other identified molecules in NIHL pathogenesis and to develop targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.